Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1958 1
1959 1
1960 3
1977 1
1999 1
2000 1
2003 2
2004 1
2006 1
2007 1
2009 2
2011 1
2012 2
2013 3
2014 1
2015 1
2016 2
2017 4
2018 1
2019 2
2020 3
2021 3
2022 3
2023 9
2024 11
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pembrolizumab in HER2-Positive Gastric Cancer.
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yañez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin S, Van Cutsem E, Tabernero J, Luo S, Mahave M, Tang Y, Lowery M, Monteiro MMF, Xu L, Shih CS, Sharan KP, Bhagia P, Rha SY. Janjigian YY, et al. Among authors: monteiro mmf. N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282917 Free PMC article. Clinical Trial. No abstract available.
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.
Bonadio RC, de Sousa IM, Balint FC, Comini ACM, Tavares MC, Madasi F, Bines J, Ferreira RDP, Rosa DD, Santos CL, de Souza ZS, Assad-Suzuki D, de Araújo JAP, Gagliato DM, Dos Anjos CH, Zucchetti BM, Ferrari A, de Brito ML, Cangussu R, Monteiro MMF, Hoff PM, Testa L, Barroso-Sousa R. Bonadio RC, et al. Among authors: monteiro mmf. NPJ Breast Cancer. 2024 Aug 14;10(1):73. doi: 10.1038/s41523-024-00676-w. NPJ Breast Cancer. 2024. PMID: 39143082 Free PMC article.
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
Bonadio RC, Tavares MC, Balint FC, de Sousa IM, Comini ACM, Madasi F, Bines J, Ferreira RDP, Rosa DD, Santos CL, de Souza ZS, Assad-Suzuki D, de Araújo JAP, Gagliato DM, Dos Anjos CH, Zucchetti BM, Ferrari A, de Brito ML, Cangussu R, Monteiro MMF, Hoff PM, Testa L, Estevez-Diz MDP, Barroso-Sousa R. Bonadio RC, et al. Among authors: monteiro mmf. Breast Cancer Res Treat. 2025 May;211(1):131-137. doi: 10.1007/s10549-025-07628-3. Epub 2025 Feb 3. Breast Cancer Res Treat. 2025. PMID: 39899161
59 results